Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

13 May, 2021

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia
Photo by Felix Fuchs on Unsplash

– Shifa is a drug discovery company developing an oral small molecule PCSK9/LDLR-antagonist, P-21, to treat dyslipidemia, announced their launch with a seed investment from Xontogeny, LLC.
– Xontogeny is a investment company that provides funding and expertise to early stage companies.
– P-21 acts as a PCSK9/LDLR-antagonist to modulate the degradation of the LDLR in the liver, thereby regulating cholesterol homeostasis.
– The management team includes Sherin Abdel-Meguid as President.
– The Board of Directors will be comprised of Chris Garabedian, CEO of Xontogeny, Gianna Hoffman-Luca, Senior Associate at Xontogeny, Shaker Mousa, Professor and Chairman at Albany College of Pharmacy and Health Sciences, and Sherin Abdel-Meguid, President of Shifa.

Biotechnology North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: